Welcome to our dedicated page for Sagimet Biosciences news (Ticker: SGMT), a resource for investors and traders seeking the latest updates and insights on Sagimet Biosciences stock.
Sagimet Biosciences Inc. (NASDAQ: SGMT) is a clinical-stage biopharmaceutical company developing oral fatty acid synthase (FASN) inhibitors for metabolic and fibrotic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe acne. The news flow around SGMT reflects its progress in clinical development, licensing collaborations, and capital markets activity.
Company announcements frequently highlight clinical trial milestones for its lead candidate denifanstat, including results from the Phase 2b FASCINATE-2 trial in MASH and Phase 3 acne data generated by its license partner in China. News items also cover secondary analyses using AI-based digital pathology and spatial computational histology to characterize fibrosis and treatment response in advanced MASH, as well as updates on a Phase 1 pharmacokinetic trial combining denifanstat with the thyroid hormone receptor beta agonist resmetirom.
Investors following SGMT news can also expect updates on Sagimet’s second oral FASN inhibitor, TVB-3567, which is in a Phase 1 first-in-human trial and is planned for acne development. Additional coverage includes regulatory interactions such as China’s National Medical Products Administration acceptance of a New Drug Application for denifanstat (ASC40) in acne, and Sagimet’s own disclosures about Breakthrough Therapy designation and end-of-Phase 2 interactions for denifanstat in MASH.
Beyond clinical and regulatory developments, Sagimet issues news on its license agreement with TAPI for innovative forms of resmetirom API to support a fixed-dose combination program, participation in healthcare and liver disease conferences, and periodic financial and corporate updates reported via Form 8-K. This news page aggregates those press releases and related items so readers can track the evolution of Sagimet’s FASN inhibitor pipeline and key events affecting SGMT stock.
Sagimet Biosciences (Nasdaq: SGMT) reported 2025 year-end results and clinical progress on March 11, 2026. Key items: $113.1M cash balance, completion of a Phase 1 PK trial of denifanstat plus resmetirom with no safety signals, an exclusive global license to TAPI resmetirom API, and NMPA acceptance of an NDA for denifanstat in acne.
Planned near-term milestones include a Phase 2 proof-of-concept trial in F4 MASH in 2H 2026 and anticipated Phase 2 acne studies for TVB-3567 in 2026.
Sagimet Biosciences (Nasdaq: SGMT) said management will participate in three investor conferences in early March 2026: TD Cowen on March 2 (Boston), Leerink on March 9 (Miami) and Citizens Life Sciences on March 10 (Miami).
TD Cowen and Leerink fireside chats will be webcast and archived for 90 days on the company's investor site.
Sagimet Biosciences (Nasdaq: SGMT) announced management will participate in two investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026 at 10:00 AM ET and Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 9:20 AM ET.
Both fireside chats will be webcast in the Investors & Media section at www.sagimet.com, with archived replays available for 90 days after each live event.
Sagimet (Nasdaq: SGMT) announced Ascletis reported positive 52-week safety results from an open-label Phase 3 trial of ASC40 (denifanstat) 50 mg once daily in moderate-to-severe acne.
The 240-subject open-label study showed denifanstat generally well tolerated through up to 52 weeks, with dry eye (5.5%) and dry skin (5.2%) as the only TEAEs ≥5%; no denifanstat-related Grade 3/4 AEs, no denifanstat-related SAEs, and efficacy endpoints improved versus 12-week data.
Ascletis (HKEX:1672) announced positive topline results from a Phase III open-label safety study of denifanstat (ASC40), a once-daily oral FASN inhibitor for moderate-to-severe acne. The 240-patient, 40-week trial reported a favorable safety and tolerability profile with mostly grade 1–2 TEAEs, no ASC40-related grade 3–4 AEs, no ASC40-related SAEs, and no deaths.
Ascletis also referenced a prior 480-patient randomized, double-blind Phase III trial that met all primary and key secondary endpoints in June 2025, and noted that a New Drug Application for ASC40 was recently accepted by the China National Medical Products Administration.
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.
Sagimet Biosciences (NASDAQ: SGMT) reported positive Phase 1 pharmacokinetic (PK) results for a once-daily combination of denifanstat and resmetirom on Dec 18, 2025. The open-label, 2-cohort PK study (NCT07216313) enrolled 40 healthy adults to evaluate multiple- and single-dose PK, drug-drug interactions, safety, and tolerability. The combination was generally well-tolerated with no serious adverse events, no treatment discontinuations, and no clinically significant lab abnormalities. Sagimet plans to use these data to pursue a Phase 2 proof-of-concept efficacy trial in MASH with F4 fibrosis, aiming to initiate the study in 2H 2026, subject to regulatory consultation, and noted a global license agreement for resmetirom API forms to support a fixed-dose combination development.
Sagimet Biosciences (Nasdaq: SGMT) entered a global, exclusive license with TAPI for innovative forms of the resmetirom API to support Sagimet’s fixed‑dose combination (FDC) program combining resmetirom with denifanstat.
The company has an ongoing Phase 1 pharmacokinetic trial of the denifanstat‑resmetirom combination (first participants dosed in September 2025) with topline data anticipated by end of 2025. Sagimet expects to select one licensed resmetirom form for manufacture of a once‑daily FDC tablet and plans to use that FDC in a Phase 3 study; a Phase 2 in F4 MASH is estimated to start in H2 2026, subject to regulatory consultation.
Sagimet (Nasdaq: SGMT) announced that Ascletis’ parent company said China’s National Medical Products Administration accepted a New Drug Application (NDA) for denifanstat (ASC40) for the treatment of moderate to severe acne on Dec 10, 2025. Sagimet granted Ascletis an exclusive license for denifanstat in China while Sagimet retains development rights for MASH in the rest of world. The NDA filing reflects Ascletis’ Phase 3 trial in acne, in which denifanstat met all primary and secondary endpoints and was generally well tolerated.
Ascletis (HKEX:1672) announced on December 10, 2025 that the China National Medical Products Administration (NMPA) accepted its New Drug Application for denifanstat (ASC40), a once-daily oral FASN inhibitor for moderate-to-severe acne vulgaris.
The company said denifanstat completed Phase II (NCT05104125) and Phase III (NCT06192264) studies, and in Phase III met all primary, key secondary and secondary efficacy endpoints (ITT analysis) versus placebo with a favorable safety profile and no related Grade 3/4 adverse events or related serious adverse events. The Phase III results were presented at EADV on September 17, 2025. Ascletis holds exclusive Greater China rights under a license from Sagimet Biosciences (Nasdaq: SGMT).